NASDAQ OMX

Appian and Luxoft Partner to Help Life Sciences Companies Transform Digitally

Dela

RESTON, Va., Dec.  05, 2017  (GLOBE NEWSWIRE) - Appian (NASDAQ:APPN), a leading low-code and business process management  platform provider, and Luxoft Holding, Inc (NYSE:LXFT), a leading provider of software development services and innovative IT solutions, today announced a global partnership to deliver end-to-end, low-code solutions to Life Sciences companies around the world.

Organizations are using software applications to become agile across the business. The Appian platform helps businesses streamline clinical operations, manage regulatory compliance in real time, create immediate innovation throughout the product lifecycle and accelerate speed to market.

"Speed to market and enabling life altering treatments for patients faster and cheaper is a continuous aspiration for all of us in the Life Sciences. Technology and software are finally getting to the point where we can make a real difference," says Evi Cohen, VP Global Pharma & Life Sciences at Appian. "The right platform in the right hands will permit us to move the needle here. This is why we are joining hands with Luxoft."

The Appian low-code platform combines technical software with a user interface simple enough for any employee to use. This means companies can quickly build and deploy custom web and mobile applications, increasing productivity while also saving costs. Appian is used across a broad range of functions but a few focus areas for life sciences include:

  • Clinical Operations: Organizations leveraging Appian have seen numerous benefits, including but not limited to; reduced start-up cycle times by 60 percent, reduced cycle time (end-to-end) by 32 percent, 50 percent reduction in cycle times from RFP development to contract execution and reduced average cycle times to 60 days.
  • Regulatory Compliance: The Appian Platform has advanced business process management capabilities that allow you to automate, monitor, and control regulatory efforts during each step of a product's lifecycle, so applications and processes are compliant throughout the entire process.
  • GxP Compliance: Organizations in the cloud can maintain GxP compliance and data integrity on the Appian Cloud by ensuring audit trails, establishing service level agreements (SLAs), and monitoring changes.
  • Regulatory Information Management: The Appian approach to Regulatory Information Management (RIM) has helped life sciences organizations successfully manage a regulatory portfolio of thousands of products across over 150 countries, comprising global, regional, and local projects. Using Appian, organizations can increase submission quality and achieve over 99 percent regulatory compliance while decreasing system maintenance costs, organizational complexity, and time to market.

Luxoft will leverage its IT integration expertise, experience of providing IT services to major pharmaceutical companies and 42 global delivery centers to help companies implement these platforms.

"In areas such as drug discovery and regulatory compliance, implementing solutions efficiently and right first time is imperative," said Sam Mantle, Healthcare & Life Sciences Managing Director at Luxoft. "Appian's business process management capabilities integrated with professional services from Luxoft will allow Life Sciences companies to better meet their business challenges."

To learn more about Appian and its work across Life Sciences and Pharma, visit www.appian.com.

This press release includes forward-looking statements. All statements contained in this press release other than statements of historical facts, including, without limitation, statements regarding market adoption of the Appian low-code software platform, the results obtained by customers using the Appian low-code software development platform, and the ability of Appian to adhere to special standards and compliance requirements are forward-looking statements. The words "anticipate," believe," "continue," "estimate," "expect," "intend," "may," "will" and similar expressions are intended to identify forward-looking statements. Appian has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Appian believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. Those forward-looking statements are subject to a number of risks and uncertainties, including, without limitation, risks related to market adoption of low-code solutions to drive digital transformation and market acceptance of the Appian platform, risks related to Appian's ability to meet its customers' needs by scaling its business sufficiently quickly, continuing to innovate and provide a useful platform, and providing satisfactory deployment services, risks related to potential security breaches and unauthorized access to Appian's platform or customer data, risks related to Appian's ability to meet special standards or requirements imposed by governmental and other highly regulated entities, and the risks and uncertainties set forth in the "Risk Factors" section of Appian's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission on November 2, 2017, and subsequent reports that Appian has filed with the Securities and Exchange Commission. Moreover, Appian operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Appian's management to predict all risks, nor can Appian assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Appian may make. In light of these risks, uncertainties and assumptions, Appian cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. Appian is under no duty to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations, except as required by law.

About Luxoft

Luxoft (NYSE:LXFT) is a global IT service provider of innovative technology solutions that delivers measurable business outcomes to multinational companies. Its offerings encompass strategic consulting, custom software development services, and digital solution engineering. Luxoft enables companies to compete by leveraging its multi-industry expertise in the financial services, automotive, communications, and healthcare & life sciences sectors. Its managed delivery model is underpinned by a highly-educated workforce, allowing the Company to continuously innovate upwards on the technology stack to meet evolving digital challenges.

Luxoft has more than 13,000 employees across 42 offices in 21 countries within five continents, with its operating headquarters office in Zug, Switzerland. For more information, please visit the website.

About Appian

Appian provides a leading low-code software development platform that enables organizations to rapidly develop powerful and unique applications. The applications created on Appian's platform help companies drive digital transformation and competitive differentiation. For more information, visit www.appian.com.

Media Inquiries

Patrick R. Corcoran
Global Director, External Relations
212-964-9900 ext. 2453
Press@luxoft.com
Twitter: @Luxoft

Nicole Greggs
Director, Media Relations
+1 703.260.7868
nicole.greggs@appian.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Appian Corporation via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Navigators to Acquire Belgian Specialty Insurer18.12.2017 07:30Pressmeddelande

STAMFORD, CT, December 18, 2017 - The Navigators Group, Inc. (NASDAQ:NAVG) today announced that it has entered into a share purchase agreement for the purchase of all of the shares of Assurances Continentales - Continentale Verzekeringen NV ("ASCO") and Bracht, Deckers & Mackelbert NV ("BDM").  ASCO and BDM are both based in Antwerp, Belgium. The proposed acquisition is part of Navigators' strategy of expanding its well-established specialty insurance expertise to more brokers and insureds across Europe. ASCO is a specialty insurance company offering marine and property and casualty insurance. BDM is an insurance underwriting agency that underwrites risk coverage in niche markets on behalf of ASCO and a number of major international insurers. Additionally, as part of the transaction, Navigators will acquire all the shares of Canal Re SA, a Luxembourg reinsurance company that is a wholly-owned subsidiary of ASCO.  The acquisition reinforces Navigators' presence in the European Un

Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit15.12.2017 22:04Pressmeddelande

Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Ltd. (Nasdaq:OXFD) and QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt Stock Exchange:QIA) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN's QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products. Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved. As part of the settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million.  The settlement includes general

Algeco Scotsman Announces Acquisition of Iron Horse Ranch15.12.2017 21:32Pressmeddelande

BALTIMORE, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Algeco/Scotsman Holding S.à r.l. (together with its subsidiaries, the "Algeco Group") today announced the successful closing of the acquisition by the Algeco Group's subsidiary, Target Logistics Management, LLC ("Target Logistics"), of Iron Horse Ranch from funds managed by TDR Capital LLP ("TDR"). The acquisition solidifies Target Logistics' position as the single largest provider of turnkey workforce housing in the U.S., including a network of eight lodges and 2,119 beds in the Permian Basin. With the acquisition, Target Logistics' Permian Basin lodge network now includes Texas lodges in Pecos, Mentone, San Angelo and two in Odessa, along with two lodges in Carlsbad and Lovington, New Mexico. Additionally, Target Logistics adds Eagle Ford lodges in Cameron and Yorktown, Texas. Diarmuid Cummins, CEO Algeco Scotsman: "Today we announce the completion of the second of two strategic acquisitions which we flagged earlier

Repurchase of own shares in Momentum Group AB (publ)15.12.2017 15:25Pressmeddelande

In accordance with the authorisation issued by the Extraordinary General Meeting of Shareholders held on 28 November 2017, Momentum Group AB (publ) has repurchased 28,800 Class B shares at an average price of SEK 103.34 per share. After the repurchase, Momentum Group AB's current holding of treasury shares amounts to 28,800 Class B shares, corresponding to 0.1 percent of the total number of shares and 0.1 percent of the total number of votes. The total number of shares in Momentum Group AB, including those held by the Company, amounts to 28,265,416, of which 1,062,436 are Class A shares and 27,202,980 are Class B shares. The total number of votes in Momentum Group AB is 37,827,340. Stockholm, 15 December 2017 Momentum Group AB (publ) For further information, please contact: Mats Karlqvist, Head of Investor Relations - Tel: +46 70 660 31 32 This information was submitted for publication on 15 December 201

Återköp av egna aktier i Momentum Group AB (publ)15.12.2017 15:25Pressmeddelande

I enlighet med bemyndigandet från den extra bolagsstämman den 28 november 2017 har Momentum Group AB (publ) återköpt 28 800 aktier av serie B till en genomsnittskurs av 103,34 SEK per aktie. Momentum Group ABs aktuella innehav av egna aktier efter återköpet uppgår till 28 800 aktier av serie B, vilket motsvarar 0,1 procent av totalt antal aktier och 0,1 procent av totalt antal röster. Det totala antalet aktier i Momentum Group AB, inklusive de av bolaget ägda aktierna, uppgår till 28 265 416 st, av vilka 1 062 436 är aktier av serie A och 27 202 980 är aktier av serie B. Det totala antalet röster i Momentum Group AB är 37 827 340. Stockholm den 15 december 2017 Momentum Group AB (publ) För ytterligare information vänligen kontakta: Mats Karlqvist, Head of Investor Relations - telefon 070-660 31 32 Informationen lämnades för offentliggörande den 15 december 2017 kl. 15:15 CET.  

Elemica Named to Food Logistics Top 100 List15.12.2017 13:55Pressmeddelande

11th Consecutive Win for Delivering Value Across Clients' Supply Chains WAYNE, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Elemica, the leading  Business Network for the process industries, announces the company has been named to Food Logistics magazine's FL100+ Award for the 11th year. The FL100+ list recognizes leading software and technology providers in the food and beverage industry.  Elemica was chosen for helping agricultural and food ingredient businesses conduct more efficient and error free commerce across their community of suppliers, customers and logistics providers - delivering value through lower operating expenses and working capital costs. "We are honored to be included for the past eleven years on the Food Logistics FL100+ list for helping companies improve efficiencies and generate value from their supply chains," said John Blyzinskyj, CEO of Elemica. "Automating business processes, enabling end-to-end visibility, and providing a platform for

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum